18267-36-2

Usage

Uses

Used in Fragrance and Flavoring Industry:
Ethyl 3-hydroxy-3-methylbutyrate is used as a fragrance and flavoring agent for its appealing fruity scent and taste, enhancing the sensory profiles of perfumes, lotions, and food products.
Used in Perfume Production:
Ethyl 3-hydroxy-3-methylbutyrate is used as a scent enhancer in perfumes, providing a pleasant, fruity aroma that contributes to the overall fragrance experience.
Used in Cosmetics:
In the cosmetics industry, ethyl 3-hydroxy-3-methylbutyrate is used as a flavoring agent in lotions and other skincare products, adding a sweet, fruity scent that improves the sensory appeal of these products.
Used in Food and Beverage Industry:
Ethyl 3-hydroxy-3-methylbutyrate is used as a flavoring agent in a variety of food and beverage products, imparting a fruity taste that enhances the overall flavor profile of these products.
Used in Consumer Goods Production:
Ethyl 3-hydroxy-3-methylbutyrate is widely employed in the production of consumer goods, where it serves to improve the scent and flavor profiles, making these products more appealing to consumers.

InChI:InChI=1/C7H14O3/c1-4-10-6(8)5-7(2,3)9/h9H,4-5H2,1-3H3

Upstream product

• 1823-52-5 4,4-dimethyloxetan-2-one 
• 64-17-5 ethanol 
• 20411-76-1 4-ethoxy-2-methylbut-3-yn-2-ol 
• 32449-00-6 acetone; sodium acetone 
• 141-78-6 ethyl acetate 
• 105-36-2 ethyl bromoacetate 
• 67-64-1 acetone 
• 2678-54-8 ketene diethyl acetal 
• 71-43-2 benzene 
• 7647-01-0 hydrogenchloride 
• 75-03-6 ethyl iodide 
• 625-08-1 3-Hydroxy-3-methylbutyric acid 
• 64-19-7 acetic acid 
• 1772-43-6 2,4,4-trimethyl oxazoline 

Downstream Products

• 93646-33-4 3-methyl-crotonic acid-(2-chloro-N-methyl-anilide) 
• 541-47-9 3-Methylbutenoic acid 
• 638-10-8 ethyl 3-methylbut-2-enoate 
• 17207-42-0 3-benzoylamino-3-methylbutanoic acid 
• 1186507-38-9 2-[(1-benzyl-5-methoxy-1H-indazol-3-yl)methoxy]-2-methylpropanoic acid 
• 31912-02-4 ethyl 2-nitrophenylacetate 
• 2122-70-5 ethyl 2-(1-naphthyl)acetate 
• 66298-58-6 methyl 2-(2-ethoxy-2-oxo-ethyl)benzoate 
• 944264-99-7 3-fluoro-3-methylbutan-1-ol 
• 625-08-1 3-Hydroxy-3-methylbutyric acid 

Relevant academic research and scientific papers

Chemo-enzymatic synthesis of novel β-hydroxy-β-methylbutryric acid (HMB)-medium chain triacylglycerol (MCT) complexes

β-Hydroxy-β-methylbutyrate (HMB) is reported to have ergogenic benefits such as reducing muscle wasting, promoting exercise performance and skeletal muscle hypertrophy. When used as a dietary feed, it has been found to improve colostral milk fat and the growth of piglets. Medium chain triacylglycerols (MCT) are a good energy source as they can be subjected to β-oxidation in the liver without being stored as fats. When used as animal feed, HMB-MCT complexes are reported to stimulate growth and produce leaner meat product. A high yield two-steps chemo-enzymatic pathway for synthesis of HMB-MCT complexes has been developed. Ethyl HMB ester was first synthesized using a chemical catalyst. Following that, it was transesterified with MCT by using a biocatalyst. Approximately 85 wt% of HMB-MCT complexes can be achieved using this two-step synthetic pathway. The reaction mechanism and some of the reaction parameters were also briefly elucidated.

Synthesis of 4-alkoxycarbonyl-butenolides by uncatalyzed one-pot cyclization of 1,3-bis(silyloxy)alk-1-enes with oxalyl chloride

3-Hydroxy-4-alkoxycarbonyl-butenolides were prepared by one-pot cyclizations of 1,3-bis(silyloxy)alk-1-enes with oxalyl chloride.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.